Tucked away inside Novartis' fourth-quarter results update this morning is the news that the company has pulled the plug on a drug candidate for Huntington's disease after
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
